Status:
RECRUITING
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
Lead Sponsor:
Erasmus Medical Center
Conditions:
Non Small Cell Lung Cancer
Liquid Biopsy
Eligibility:
All Genders
18+ years
Brief Summary
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a ty...
Detailed Description
This is an observational study in pulmonary oncology patients treated with TKI. Ideally before start of therapy, at week 4, 8 12, and then every 4-8 weeks (following the standard of care clinical path...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Able to understand the written informed and able to give informed consent
- Locally advanced or metastatic NSCLC with oncogenic driver mutation
- Treatment with TKI according to standard of care
Exclusion
- Unable to draw blood for study purposes
Key Trial Info
Start Date :
February 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2031
Estimated Enrollment :
1300 Patients enrolled
Trial Details
Trial ID
NCT05221372
Start Date
February 2 2017
End Date
January 1 2031
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, Netherlands